Jazz Pharmaceuticals (JAZZ) Income towards Parent Company (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Income towards Parent Company of $293.1 million for Q1 2026, up 418.59% year-over-year from $56.5 million in Q1 2025, and up 44.02% quarter-over-quarter from $203.5 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Income towards Parent Company (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Income towards Parent Company history runs 16 years deep, the most recent figure standing at $293.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 418.59% year-over-year to $293.1 million; the TTM figure through Mar 2026 stood at $29.7 million (down 93.85% YoY), while the FY2025 annual figure was -$355.4 million, down 163.27% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $293.1 million, up from $203.5 million in the prior quarter.
- The five-year high for Income towards Parent Company was $293.1 million in Q1 2026, with the low at -$718.4 million in Q2 2025.
- The 5-year median for Income towards Parent Company is $94.6 million (2023), against an average of $41.4 million.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company sank 641.44% in 2022, then soared 1116.53% in 2023.
- Jazz Pharmaceuticals' Income towards Parent Company stood at -$240.0 million in 2022, then surged by 139.44% to $94.6 million in 2023, then jumped by 102.0% to $191.1 million in 2024, then advanced by 6.47% to $203.5 million in 2025, then soared by 44.02% to $293.1 million in 2026.
- Business Quant data shows JAZZ's Income towards Parent Company at $293.1 million in Q1 2026, $203.5 million in Q4 2025, and $251.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.90 Mn |
| Mar 31, 2026 | 293.10 Mn |
| Dec 31, 2025 | 203.51 Mn |
| Sep 30, 2025 | 251.44 Mn |
| Jun 30, 2025 | -718.35 Mn |
| Mar 31, 2025 | -92.00 Mn |
| Dec 31, 2024 | 191.15 Mn |
| Sep 30, 2024 | 215.34 Mn |
| Jun 30, 2024 | 168.63 Mn |
| Mar 31, 2024 | -13.27 Mn |
| Dec 31, 2023 | 94.63 Mn |
| Sep 30, 2023 | 146.72 Mn |
| Jun 30, 2023 | 106.08 Mn |
| Mar 31, 2023 | 70.43 Mn |
| Dec 31, 2022 | -239.95 Mn |
| Sep 30, 2022 | -17.13 Mn |
| Jun 30, 2022 | 37.11 Mn |
| Mar 31, 2022 | 5.79 Mn |
| Dec 31, 2021 | -32.36 Mn |
| Sep 30, 2021 | -49.53 Mn |